Delisting risk
Alps (ALPS)
Combines biotechnology research, medical services, and wellness solutions around predictive, preventive, and precision medicine.
$0.3915
Pre-market+0.01 (+3.05%)
At close$0.3799(−2.46%)
In millions of USD, except per-share figures
| In millions | Q4 FY22Dec 2022 | Q1 FY23Mar 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q4 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | −17 | 49 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 |
| Cost of revenue | 83 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Gross profit | −120 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| 79 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 67 | 0 | 0 | |
| 5 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 66 | 0 | 0 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 0 |
| General & administrative | 5 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 67 | 0 | 0 |
| Other expenses | 74 | −3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Operating income | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 | −65 | 0 | 0 |
| 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
| Interest income | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | −18 | −6 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 0 |
| Other non-operating income | −1 | −1 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | 1 | 1 | 0 | 0 | 0 | 0 | 0 | −1 | −65 | −1 | −1 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 1 | 1 | 0 | 0 | 0 | 0 | 0 | −1 | −65 | −1 | −1 |
| Net income | 1 | 1 | 0 | 0 | 0 | 0 | 0 | −1 | −65 | −1 | −1 |
| EPS, basic | $0.03 | $0.05 | $0.02 | −$0.06 | −$0.04 | −$0.02 | −$0.05 | −$0.20 | −$14.11 | −$0.24 | −$0.24 |
| EPS, diluted | $0.03 | $0.05 | $0.02 | −$0.06 | −$0.04 | −$0.02 | −$0.05 | −$0.20 | −$14.11 | −$0.24 | −$0.24 |
| Weighted average shares, basic | 34 | 35 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 4 | 4 |
| Weighted average shares, diluted | 54 | 55 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 4 | 4 |
| EBITDA | 39 | 22 | 0 | 0 | 0 | 0 | 0 | 0 | −66 | 0 | 0 |
| Depreciation & amortization | 35 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | −66 | 0 | 0 |